おすすめの製品
グレード
pharmaceutical primary standard
APIファミリー
citalopram
メーカー／製品名
USP
アプリケーション
pharmaceutical (small molecule)
フォーマット
neat
SMILES記法
[Cl-].[N+H](C(C)C=C(c2ccccc2)c1ccccc1)(C)C
InChI
1S/C18H21N.ClH/c1-15(19(2)3)14-18(16-10-6-4-7-11-16)17-12-8-5-9-13-17;/h4-15H,1-3H3;1H
InChI Key
ZVTAYVQUGPGRAF-UHFFFAOYSA-N
類似した製品をお探しですか？ 訪問 製品比較ガイド
詳細
この製品は薬局方標準品です。発行元の薬局方により製造・供給されています。MSDSを含む製品情報などの詳しい情報は、発行元の薬局方のウェブサイトよりご確認ください。
アプリケーション
Citalopram Related Compound F USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monograph such as Citalopram Tablets
アナリシスノート
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
その他情報
Sales restrictions may apply.
関連製品
製品番号
詳細
価格
シグナルワード
Danger
危険有害性情報
注意書き
危険有害性の分類
Acute Tox. 3 Oral
保管分類コード
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
WGK
WGK 3
引火点(°F)
Not applicable
引火点(℃)
Not applicable
最新バージョンのいずれかを選択してください：
B Ebert et al.
Pharmacology & toxicology, 82(3), 157-160 (1998-04-29)
The opioid, ketobemidone, has previously been shown to be a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist. In Denmark, ketobemidone is available in a formulation which contains ketobemidone and a spasmolytic compound, (RS)-3-dimethylamino-1,1-diphenylbut-1-ene, hydrochloride (A29), in a one to five ratio. Using
Histamine release from human basophils and isolated rat mast cells induced by ketobemidone, pethidine and the spasmolytic A29.
N Grosman
Acta pharmacologica et toxicologica, 50(1), 78-80 (1982-01-01)
J C Raeder et al.
Acta anaesthesiologica Scandinavica, 30(7), 502-506 (1986-10-01)
A double-blind comparison of the effect of Ketogan (ketobemidone and A-29, an anticholinergic and spasmolytic agent) and morphine + scopolamine as premedication was performed in 113 women admitted for abortion and in 114 women admitted for gynaecological dilatation and curettage.
M Kjaer et al.
Acta oncologica (Stockholm, Sweden), 27(5), 583-589 (1988-01-01)
Thirteen cancer patients with moderate to severe chronic pain of malignant origin on treatment with Ketogan tablets were included in an open non-randomized cross-over study comparing the analgesic effect, side effects and serum concentrations of Ketogan tablets and mixture. The
P Anderson et al.
European journal of clinical pharmacology, 19(3), 217-223 (1981-02-01)
The pharmacokinetic constants and rectal bioavailability of the narcotic analgesic ketobemidone were determined in six male patients after surgery. Plasma concentrations were measured following intravenous administration of Ketogin 2 ml, containing ketobemidone chloride 10 mg, and a spasmolytic compound N,N-dimethyl-3,3-diphenyl-1-methylallylamine
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら（テクニカルサービス）